Vanguard Capital Management’s Neuropace NPCE Stock Holding History
Bought
Maintained
Sold
Other funds holding NPCE
Vanguard Capital Management's NPCE Position: Q3 2026 in Review
Vanguard Capital Management increased its Neuropace (NPCE) stake by 0.58% in Q3 2026, buying an estimated $105K and bringing the position to 1,234,175 shares worth $17M. The position accounts for ﹤0.01% of the portfolio, ranked #2481.
Vanguard Capital Management first reported a position in NPCE in Q1 2026 and has held it in 3 quarters since. The position peaked at $19.5M in Q2 2026. 105 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.
- Vanguard Capital Management held 1,234,175 shares of Neuropace worth $17M as of Q3 2026.
- Vanguard Capital Management bought 7,103 Neuropace shares in Q3 2026, an estimated $105K.
- Neuropace made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2481 holding.
- Vanguard Capital Management first reported a position in Neuropace in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Neuropace position peaked at $19.5M in Q2 2026.
- 105 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.